SEC Form SC 13G filed by Exact Sciences Corporation

10/7/24 11:37:08 AM ET

Medical Specialities

Health Care

Get the next $EXAS alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 EXACT SCIENCES CORP COMMON STOCK Cusip #30063P105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #30063P105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 21,499,163 Item 6: 0 Item 7: 22,042,464 Item 8: 0 Item 9: 22,042,464 Item 11: 11.897% Item 12: HC Cusip #30063P105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 22,042,464 Item 8: 0 Item 9: 22,042,464 Item 11: 11.897% Item 12: IN Item 1(a). Name of Issuer: EXACT SCIENCES CORP Item 1(b). Address of Issuer's Principal Executive Offices: 5505 ENDEAVOR LANE MADISON, WI 53719 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 30063P105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 22,042,464 (b) Percent of Class: 11.897% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 22,042,464 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of EXACT SCIENCES CORP. No one other person's interest in the COMMON STOCK of EXACT SCIENCES CORP is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. October 4, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on October 4, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of EXACT SCIENCES CORP at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $EXAS alert in real time by email

Recent Analyst Ratings for

$EXAS

Date	Price Target	Rating	Analyst
4/10/2025	$60.00	Outperform	Mizuho
3/13/2025	$52.00	Sector Perform	RBC Capital Mkts
1/23/2025	$70.00	Overweight	Barclays
8/28/2024	$75.00	Overweight	Wells Fargo
6/27/2024	$70.00	Sector Outperform	Scotiabank
6/3/2024	$75.00	Buy	Jefferies
1/2/2024	$91.00	Hold → Buy	The Benchmark Company
12/14/2023	$90.00	Buy	Guggenheim

More analyst ratings

SEC Form SC 13G filed by Exact Sciences Corporation

10/7/24 11:37:08 AM ET

$EXAS

Medical Specialities

Health Care

Get the next $EXAS alert in real time by email

Recent Analyst Ratings for

$EXAS

Date	Price Target	Rating	Analyst
4/10/2025	$60.00	Outperform	Mizuho
3/13/2025	$52.00	Sector Perform	RBC Capital Mkts
1/23/2025	$70.00	Overweight	Barclays
8/28/2024	$75.00	Overweight	Wells Fargo
6/27/2024	$70.00	Sector Outperform	Scotiabank
6/3/2024	$75.00	Buy	Jefferies
1/2/2024	$91.00	Hold → Buy	The Benchmark Company
12/14/2023	$90.00	Buy	Guggenheim

More analyst ratings

SEC Form SC 13G filed by Exact Sciences Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$EXAS

SEC Form SC 13G filed by Exact Sciences Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$EXAS

$EXAS
Press Releases

Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

Exact Sciences to Participate in November Investor Conference

$EXAS
Insider Trading

SVP, General Counsel & Sec Herriott James sold $105,120 worth of shares (1,500 units at $70.08), decreasing direct ownership by 11% to 12,585 units (SEC Form 4)

EVP, GM, Precision Oncology Baranick Brian sold $200,289 worth of shares (2,858 units at $70.08), decreasing direct ownership by 11% to 22,368 units (SEC Form 4)

Director Zanotti Katherine S sold $780,000 worth of shares (12,000 units at $65.00), decreasing direct ownership by 16% to 60,759 units (SEC Form 4)

$EXAS
SEC Filings

SEC Form 10-Q filed by Exact Sciences Corporation

Exact Sciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

$EXAS
Insider Purchases

President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

$EXAS
Analyst Ratings

Mizuho initiated coverage on Exact Sciences with a new price target

RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

Barclays initiated coverage on Exact Sciences with a new price target

$EXAS
Financials

Exact Sciences Announces Third Quarter 2025 Results

Exact Sciences Schedules Third Quarter 2025 Earnings Call

Exact Sciences Announces Second Quarter 2025 Results

$EXAS
Large Ownership Changes